A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALL

Summary

This is a multicenter, prospective, phase II study for adult de novo Philadelphia chromosome-positive acute lymphoid leukemia (Ph+ ALL) based on the combination of Olverembatinib and Blinatumomab. Olverembatinib will be taken 40mg qod from the time of diagnosis, and Blinatumomab will be given intravenously up to five cycles.

Timeline

Start

2023-07-01

Primary completion

2025-06-30

Completion

2030-06-30

Drugs

Indications